WO2006125962A3 - T cell receptors which specifically bind to vygfvracl-hla-a24 - Google Patents

T cell receptors which specifically bind to vygfvracl-hla-a24 Download PDF

Info

Publication number
WO2006125962A3
WO2006125962A3 PCT/GB2006/001857 GB2006001857W WO2006125962A3 WO 2006125962 A3 WO2006125962 A3 WO 2006125962A3 GB 2006001857 W GB2006001857 W GB 2006001857W WO 2006125962 A3 WO2006125962 A3 WO 2006125962A3
Authority
WO
WIPO (PCT)
Prior art keywords
vygfvracl
hla
cell receptors
specifically bind
tcrs
Prior art date
Application number
PCT/GB2006/001857
Other languages
French (fr)
Other versions
WO2006125962A2 (en
Inventor
Bent Karsten Jakobsen
Yi Li
Original Assignee
Avidex Ltd
Bent Karsten Jakobsen
Yi Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/002078 external-priority patent/WO2005116646A1/en
Priority claimed from GBGB0524477.7A external-priority patent/GB0524477D0/en
Application filed by Avidex Ltd, Bent Karsten Jakobsen, Yi Li filed Critical Avidex Ltd
Priority to DE602006020037T priority Critical patent/DE602006020037D1/en
Priority to AT06727144T priority patent/ATE497976T1/en
Priority to CN2006800182554A priority patent/CN101389652B/en
Priority to EP06727144A priority patent/EP1885754B1/en
Priority to JP2008512901A priority patent/JP5149789B2/en
Priority to US11/915,190 priority patent/US8017730B2/en
Publication of WO2006125962A2 publication Critical patent/WO2006125962A2/en
Publication of WO2006125962A3 publication Critical patent/WO2006125962A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Abstract

The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting tha complex.
PCT/GB2006/001857 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24 WO2006125962A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE602006020037T DE602006020037D1 (en) 2005-05-25 2006-05-19 Specifically to VYGFVRACL-HLA-A24 Binding T-cell Receptors
AT06727144T ATE497976T1 (en) 2005-05-25 2006-05-19 T CELL RECEPTORS BINDING SPECIFICALLY TO VYGFVRACL-HLA-A24
CN2006800182554A CN101389652B (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to VYGFVRACL-HLA-A24
EP06727144A EP1885754B1 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24
JP2008512901A JP5149789B2 (en) 2005-05-25 2006-05-19 T cell receptor that specifically binds to VYGFVRACL-HLA-A24
US11/915,190 US8017730B2 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to VYGFVRACL-HLA-A24

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2005/002078 WO2005116646A1 (en) 2004-05-26 2005-05-25 Method for the identification of a polypeptide which binds to a given pmhc complex
GBPCT/GB2005/002078 2005-05-25
GB0524477.7 2005-11-30
GBGB0524477.7A GB0524477D0 (en) 2005-11-30 2005-11-30 Isolated T cell receptors which specifically bind to vygfvracl-hla-24

Publications (2)

Publication Number Publication Date
WO2006125962A2 WO2006125962A2 (en) 2006-11-30
WO2006125962A3 true WO2006125962A3 (en) 2007-02-01

Family

ID=37395870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001857 WO2006125962A2 (en) 2005-05-25 2006-05-19 T cell receptors which specifically bind to vygfvracl-hla-a24

Country Status (2)

Country Link
EP (1) EP1885754B1 (en)
WO (1) WO2006125962A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06624A (en) 2005-10-18 2015-07-10 Univ Colorado
IL287311B1 (en) 2008-05-16 2024-02-01 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
ES2856179T3 (en) 2012-07-20 2021-09-27 Taiga Biotechnologies Inc Empowered Reconstitution and Self-Reconstitution of the Hematopoietic Compartment
NZ704157A (en) * 2012-07-27 2018-08-31 Univ Illinois Engineering t-cell receptors
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
RU2020132040A (en) 2015-05-20 2020-10-12 Те Брод Инститьют Инк. GENERAL NEOANTIGENS
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
IL293611A (en) 2016-12-02 2022-08-01 Taiga Biotechnologies Inc Nanoparticle formulations
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
FI3580561T3 (en) 2017-02-12 2023-12-12 Biontech Us Inc Hla-based methods and compositions and uses thereof
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
US20210293783A1 (en) 2017-04-18 2021-09-23 The General Hospital Corporation Compositions for detecting secretion and methods of use
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
CA3035209A1 (en) 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN111511388A (en) 2017-09-21 2020-08-07 博德研究所 Systems, methods, and compositions for targeted nucleic acid editing
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210355522A1 (en) 2018-08-20 2021-11-18 The Broad Institute, Inc. Inhibitors of rna-guided nuclease activity and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
AU2019404547A1 (en) 2018-12-21 2021-07-22 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044004A2 (en) * 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
WO2005116075A1 (en) * 2004-05-26 2005-12-08 Avidex Ltd. High affinity telomerase t cell receptors
WO2006064176A1 (en) * 2004-12-16 2006-06-22 Avidex Ltd Assays for superantigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044004A2 (en) * 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
WO2005116075A1 (en) * 2004-05-26 2005-12-08 Avidex Ltd. High affinity telomerase t cell receptors
WO2006064176A1 (en) * 2004-12-16 2006-06-22 Avidex Ltd Assays for superantigens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAI JUNKO ET AL: "Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes", BLOOD, vol. 97, no. 9, 1 May 2001 (2001-05-01), pages 2903 - 2907, XP002408551, ISSN: 0006-4971 *
COLE DAVID K ET AL: "Crystal structure of HLA-A*2402 complexed with a telomerase peptide", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 36, no. 1, January 2006 (2006-01-01), pages 170 - 179, XP002408552, ISSN: 0014-2980 *
LI YI ET AL: "Directed evolution of human T-cell receptors with picomolar affinities by phage display", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 3, March 2005 (2005-03-01), pages 349 - 354, XP002336795, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
EP1885754A2 (en) 2008-02-13
EP1885754B1 (en) 2011-02-09
WO2006125962A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2009070243A3 (en) Wise binding antibodies and epitopes
MA32190B1 (en) Antibodies to angiopoietin 1 and angiopoietin 2 and their use
WO2008042814A3 (en) Mart-1 t cell receptors
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2009022154A3 (en) Peptide with multiple epitopes
EP2175884B8 (en) Combination therapies employing gitr binding molecules
WO2008157356A3 (en) Antibody formulations
WO2008089397A3 (en) Adrb2 cancer markers
WO2009113828A3 (en) Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2009067636A3 (en) Modified insulin polypeptides and their uses
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2007104062A8 (en) Compositions and methods based on peptide binding profiling
WO2007149476A3 (en) Assays for non-apoptotic cell death and uses thereof
AU2006239318A8 (en) Cancer specific PCNA isoform binding antibodies and uses thereof
WO2010100056A3 (en) Antibodies against a proliferating inducing ligand (april)
WO2008010162A3 (en) Intracellular targeting of molecules
EP2135075B8 (en) Whole blood assay
MX2010007716A (en) COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART.
WO2006054096A3 (en) Soluble bifunctional proteins
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680018255.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008512901

Country of ref document: JP

Ref document number: 2006727144

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727144

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006727144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11915190

Country of ref document: US